Last updated: February 19, 2026
ISENTRESS HD (raltegravir) is an integrase inhibitor used in the treatment of HIV-1 infection. Its patent landscape is characterized by expiring composition of matter patents and ongoing protection for formulation, method of use, and manufacturing process patents. This analysis evaluates the current investment scenario for ISENTRESS HD, considering its market position, competitive landscape, and patent expiry timelines.
What is the Market Position of ISENTRESS HD?
ISENTRESS HD is a branded prescription medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in adult and pediatric patients. It is indicated for use in combination with other antiretroviral agents.
- Indication: Treatment of HIV-1 infection in adult and pediatric patients.
- Mechanism of Action: Integrase strand transfer inhibitor (INSTI).
- Dosage Form: High-dose, once-daily tablet.
- First Approval: December 2007 (as ISENTRESS, 400 mg twice daily).
- ISENTRESS HD Approval: October 2011 (600 mg once daily).
The market for HIV treatment is dynamic, with a strong emphasis on combination therapies and long-acting injectables. ISENTRESS HD competes with other approved INSTIs, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and entry inhibitors. Its market share is influenced by factors such as efficacy, safety profile, drug-drug interaction potential, patient adherence, and cost.
What is the Patent Status of ISENTRESS HD?
The patent protection for ISENTRESS HD is multifaceted, encompassing the active pharmaceutical ingredient (API), formulations, methods of use, and manufacturing processes.
Core Composition of Matter Patents
The primary patents covering the raltegravir molecule itself have expired.
- U.S. Patent No. 7,173,040: Original patent for raltegravir, expired in December 2024. This patent claimed the compound raltegravir and its use.
- U.S. Patent No. 7,732,497: A divisional patent related to the initial filing, covering aspects of raltegravir synthesis. Expired December 2024.
The expiry of these foundational patents opens the door for generic competition.
Formulation and Method of Use Patents
Merck & Co., Inc., the originator of ISENTRESS HD, has secured patents covering specific formulations and methods of use designed to enhance the drug's profile, such as the once-daily high-dose formulation.
- U.S. Patent No. 8,299,090: Claims methods of treating HIV-1 using a specific dosage regimen of raltegravir (once daily). This patent has a term that extends to March 2027, including statutory patent term extensions.
- U.S. Patent No. 8,003,649: Claims a specific tablet formulation for raltegravir, likely related to the ISENTRESS HD dosage form. This patent is expected to expire in October 2028, with potential for patent term extension.
- U.S. Patent No. 8,563,581: Claims a tablet formulation of raltegravir. Expected to expire in October 2028, with potential for patent term extension.
These later-expiring patents provide a period of continued market exclusivity for the branded ISENTRESS HD formulation beyond the expiry of the core composition of matter patents.
Manufacturing Process Patents
Patents covering specific manufacturing processes for raltegravir can also contribute to market exclusivity by making it more difficult or costly for generic manufacturers to produce the API efficiently and cost-effectively. Specific details of these patents are often proprietary and not as broadly publicized as API or formulation patents. However, any issued patent in this area would be a critical consideration for generic entry strategies.
Orange Book Listing
The U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the "Orange Book," lists patents that claim approved drug products. As of the most recent updates, ISENTRESS HD (raltegravir) has multiple patents listed, including those mentioned above, with varying expiry dates. Generic manufacturers must demonstrate that their proposed product does not infringe on any listed patents to receive FDA approval.
What is the Competitive Landscape for ISENTRESS HD?
The HIV treatment market is highly competitive, with numerous antiretroviral drugs and combination therapies available. ISENTRESS HD faces competition from other INSTIs as well as drugs from different classes.
Direct Competition (Other INSTIs)
- Tivicay (dolutegravir) by ViiV Healthcare: A highly effective INSTI with a strong safety profile. Tivicay is often a preferred agent due to its efficacy and low potential for drug-drug interactions.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) by Gilead Sciences: A single-tablet regimen (STR) that includes elvitegravir, an INSTI.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) by Gilead Sciences: A newer STR that includes bictegravir, a potent INSTI, and has rapidly gained market share due to its efficacy and tolerability.
- Cabenuva (cabotegravir/rilpivirine) by ViiV Healthcare: The first long-acting injectable HIV treatment, offering monthly or bimonthly dosing. Cabotegravir is also an INSTI.
Competition from Other Drug Classes
- Protease Inhibitors (PIs): Kaletra (lopinavir/ritonavir), Prezista (darunavir).
- Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): Truvada (emtricitabine/tenofovir disoproxil fumarate), Descovy (emtricitabine/tenofovir alafenamide).
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Sustiva (efavirenz), Edurant (rilpivirine).
The trend towards single-tablet regimens and long-acting injectables poses a significant challenge to older, multi-pill or less convenient dosing regimens. ISENTRESS HD's once-daily formulation provides a convenience advantage over its original twice-daily dosing but still requires co-administration with other antiretroviral agents, unlike some STRs.
What are the Potential Investment Risks and Opportunities?
The investment profile for ISENTRESS HD is influenced by its patent expiry, the evolving HIV treatment landscape, and market dynamics.
Risks
- Generic Entry: The expiry of core composition of matter patents in late 2024 will allow for the introduction of generic raltegravir. Generic competition typically leads to significant price erosion for branded drugs, reducing revenue for the originator.
- Competition from Newer Agents: The rapid adoption of newer INSTIs like bictegravir (Biktarvy) and the emergence of long-acting injectables (Cabenuva) represent a significant threat to ISENTRESS HD's market share, particularly in treatment-naive populations. These newer agents often offer superior efficacy, improved safety profiles, or greater convenience.
- Market Saturation: The HIV market is mature, with established treatment guidelines and a high level of competition. It may be challenging for ISENTRESS HD to gain or maintain significant market share against superior alternatives.
- Formulation Patent Expiry: While formulation patents extend exclusivity to around 2028, generic manufacturers may explore workarounds or challenge these patents. The development of bioequivalent generic formulations could occur shortly after these patents expire.
- Reimbursement Pressures: Payers often exert pressure on drug prices, especially for older or less differentiated therapies. This can impact the profitability of ISENTRESS HD.
Opportunities
- Continued Demand for Existing Therapies: Despite the availability of newer treatments, established drugs like ISENTRESS HD can maintain a significant patient base, especially among patients who are stable on their current regimen and have no reason to switch.
- Cost-Effectiveness for Certain Markets: In some healthcare systems or for specific patient populations, generic raltegravir may offer a more cost-effective treatment option, potentially maintaining volume in certain segments.
- Pediatric Use: ISENTRESS HD has an indication for pediatric patients. If generic versions are also approved for this population, they could provide a cost-effective treatment alternative.
- Market Divestment or Licensing: The originator company (Merck) might consider divesting the rights to ISENTRESS HD or licensing opportunities to generic manufacturers or smaller pharmaceutical companies looking to enter the HIV market with established products. This could provide some residual revenue stream.
- Combination Therapies: While ISENTRESS HD is not an STR itself, it is used in combination. Generic raltegravir could be utilized in novel, fixed-dose combinations developed by other companies seeking to leverage an existing API.
What is the Timeline for Generic Entry?
Generic entry for ISENTRESS HD is anticipated following the expiry of its key composition of matter patents.
- December 2024: Expiry of U.S. Patent Nos. 7,173,040 and 7,732,497, covering the raltegravir molecule. This is the primary trigger for generic competition.
- Post-December 2024: Generic manufacturers that have filed Abbreviated New Drug Applications (ANDAs) and have demonstrated non-infringement of active patents or have successfully challenged existing patents can launch their products.
- October 2028 (and beyond): Expiry of U.S. Patent Nos. 8,003,649 and 8,563,581, related to the specific formulation of ISENTRESS HD. Generic versions designed to be bioequivalent to the original ISENTRESS HD formulation would need to navigate these patents. However, generics are often developed to be bioequivalent to the innovator drug's active ingredient and are not necessarily identical in formulation unless they infringe a formulation patent. If a generic formulation does not infringe, it could launch earlier.
The actual launch date of generic raltegravir will depend on the speed of ANDA approvals, potential litigation, and the strategic decisions of generic manufacturers.
Key Takeaways
ISENTRESS HD (raltegravir) faces imminent generic competition following the expiry of its core composition of matter patents in December 2024. While formulation patents extend some market exclusivity until approximately 2028, the market landscape for HIV treatment is characterized by intense competition from newer, often more convenient, and highly efficacious therapies, including single-tablet regimens and long-acting injectables. Investment opportunities for ISENTRESS HD are likely limited to residual revenue from continued use in existing patient populations or potential cost-effective generic market segments. Risks are primarily associated with significant price erosion due to generic entry and market share erosion by advanced competing therapies.
Frequently Asked Questions
-
When are the primary patents for raltegravir expiring in the U.S.?
The primary composition of matter patents for raltegravir, U.S. Patent Nos. 7,173,040 and 7,732,497, expire in December 2024.
-
Are there any formulation patents that could delay generic entry for ISENTRESS HD?
Yes, U.S. Patent Nos. 8,003,649 and 8,563,581, related to specific tablet formulations of raltegravir, are expected to expire in October 2028. These could impact the market entry of generics specifically mimicking the ISENTRESS HD formulation.
-
What is the main competitive challenge for ISENTRESS HD?
The main competitive challenge comes from newer integrase strand transfer inhibitors such as dolutegravir (Tivicay) and bictegravir (Biktarvy), as well as single-tablet regimens and long-acting injectable HIV therapies, which offer improved efficacy, safety, or convenience.
-
What impact does generic competition typically have on the revenue of branded drugs?
Generic competition typically leads to substantial price reductions, resulting in significant revenue erosion for the originator of the branded drug.
-
Can generic raltegravir be used in pediatric HIV treatment?
If a generic version of raltegravir receives FDA approval for pediatric use, it can be utilized in this patient population, offering a potentially more affordable treatment option.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book website] (specific URL not provided as it is a dynamic database)
[2] Merck & Co., Inc. (2023). ISENTRESS HD® (raltegravir) Prescribing Information.
[3] Various patent databases (e.g., USPTO, Google Patents) for patent numbers and expiry dates. (Specific database URLs not provided as they are general search platforms)
[4] ViiV Healthcare. (n.d.). Tivicay (dolutegravir) Prescribing Information.
[5] Gilead Sciences, Inc. (n.d.). Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Prescribing Information.
[6] ViiV Healthcare. (n.d.). Cabenuva (cabotegravir/rilpivirine) Prescribing Information.
